Metabet SR tablets prolonged-release

Land: Armenien

Språk: engelska

Källa: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ladda ner Bipacksedel (PIL)
03-12-2019
Ladda ner Produktens egenskaper (SPC)
03-12-2019

Aktiva substanser:

metformin (metformin hydrochloride)

Tillgänglig från:

Morningside Pharmaceuticals Ltd

ATC-kod:

A10BA02

INN (International namn):

metformin (metformin hydrochloride)

Dos:

1000mg

Läkemedelsform:

tablets prolonged-release

Enheter i paketet:

(28/2x14/) in blister

Receptbelagda typ:

Prescription

Bemyndigande status:

Registered

Tillstånd datum:

2019-12-03

Bipacksedel

                                1
PACKAGE LEAFLET: INFORMATION FOR THE USER
METABET SR 1000 MG PROLONGED RELEASE TABLETS
Metformin hydrochloride
This medicine is intended for ADULT patients only.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you only. Do not pass it on to
others. It may
harm them, even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor or pharmacist. This
includes any
possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Metabet SR is and what it is used for
2.
What you need to know before you take Metabet SR
3.
How to take Metabet SR
4.
Possible side effects
5.
How to store Metabet SR
6.
Contents of the pack and other information
1. WHAT METABET SR IS AND WHAT IT IS USED FOR
Metabet SR 1000mg prolonged release tablets contain the active
ingredient metformin
hydrochloride
and
belong
to
a
group
of
medicines
called
biguanides,
used
in
the
treatment of Type 2 (non-insulin dependent) diabetes mellitus.
Metabet SR is used together with diet and exercise to lower the risk
of developing Type 2
diabetes in overweight adults, when diet and exercise alone for 3 to 6
months have not
been enough to control blood glucose (sugar). You are at high risk of
developing Type 2
diabetes if you have additional conditions like high blood pressure,
age above 40 years,
an abnormal amount of lipids (fat) in the blood or a history of
diabetes during pregnancy.
The
medicine
is
particularly
effective
if
you
are
aged
below
45
years,
are
very
overweight, have high blood glucose levels after a meal or developed
diabetes during
pregnancy.
Metabet SR is used for the treatment of Type 2 diabetes when diet and
exercise changes
alone have not been enough to control blood glucose (sugar). Insulin
is a hormone that
enables body tiss
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Metabet SR 1000 mg prolonged release tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each prolonged release tablet contains:
Metformin hydrochloride 1000 mg corresponding to 780 mg metformin base
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Prolonged release tablet .
Off-white coloured, oval, biconvex, film-coated tablets with score
line on one side and plain on
other side.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS

Reduction in the risk or delay of the onset of type 2 diabetes
mellitus in adult, overweight
patients with IGT* and/or IFG*, and/or increased HbA1C who are:
-
at high risk for developing overt type 2 diabetes mellitus (see
section 5.1) and
-
still progressing towards type 2 diabetes mellitus despite
implementation of intensive
lifestyle change for 3 to 6 months.
Treatment
with
Metabet
SR
/
Bolamyn
SR
/
Metformin
must
be
based
on
a
risk
score
incorporating
appropriate
measures
of
glycaemic
control
and
including
evidence
of
high
cardiovascular risk (see section 5.1).
Lifestyle modifications should be continued when metformin is
initiated, unless the patient is
unable to do so because of medical reasons.
*IGT: Impaired Glucose Tolerance; IFG: Impaired Fasting Glucose

Treatment of type 2 diabetes mellitus in adults, particularly in
overweight patients, when
dietary management and exercise alone does not result in adequate
glycaemic control.
Metabet SR / Bolamyn SR / Metformin may be used as monotherapy or in
combination with
other oral antidiabetic agents, or with insulin.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
ADULTS WITH NORMAL RENAL FUNCTION (GFR ≥ 90 ML/MIN):
_Reduction in the risk or delay of the onset of type 2 diabetes _

Metformin should only be considered where intensive lifestyle
modifications for 3 to 6
months have not resulted in adequate glycaemic control.

The therapy should be initiated with one tablet Metabet SR 500 mg once
daily with the
evening meal.

Af
                                
                                Läs hela dokumentet
                                
                            

Sök varningar relaterade till denna produkt